



06-12-03

Express Mail No. EV 335 856 012 US

RECEIVED  
JUN 11 2003  
TECH CENTER 160012900

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Application of: Jin et al.

Confirmation No.: 9862

Serial No.: 09/724,379

Art Unit: 1642

Filed: November 28, 2000

Examiner: To Be Assigned

For: RECOMBINANT RSV EXPRESSION SYSTEMS  
AND VACCINES

Attorney Docket No.: 7682-055-999

DH

**SUPPLEMENTAL INFORMATION DISCLOSURE  
STATEMENT UNDER 37 C.F.R. § 1.56**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

In accordance with the continuing duty of disclosure imposed by 37 C.F.R. § 1.56 to inform the Patent and Trademark Office of all references coming to the attention of each individual associated with the filing or prosecution of the subject application, which are or may be material to the patentability of any claim of the application, Attorneys for Applicants hereby direct the Examiner's attention to the references listed on the attached revised form PTO-1449 entitled "List of References Cited by Applicant." Legible copies of references BX to DJ are submitted herewith. Applicants respectfully request that the Examiner review the listed references and that the references be made of record in the file history of the application.

Since this Supplemental Information Disclosure Statement is being filed before the mailing of the first Office action on the merits, no fee is believed to be due according to 37 C.F.R. § 1.97(3). However, should the Patent and Trademark Office determine otherwise, please charge any required fee to Pennie & Edmonds LLP Deposit Account No. 16-1150. A copy of this sheet is enclosed for accounting purposes.

Respectfully submitted,


by: Jacqueline Benn  
Reg No. 43,492

Date: June 11, 2003

Laura A. Coruzzi

30,742  
(Reg. No.)

Laura A. Coruzzi  
PENNIE & EDMONDS LLP  
1155 Avenue of the Americas  
New York, New York 10036-2711  
(212) 790-9090



Express Mail No. EV 335 856 012 US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Jin et al.

Confirmation No.: 9862

Serial No.: 09/724,379

Art Unit: 1642

Filed: November 28, 2000

Examiner: To Be Assigned

For: RECOMBINANT RSV EXPRESSION SYSTEMS  
AND VACCINES

Attorney Docket No.: 7682-055-999

**SUPPLEMENTAL INFORMATION DISCLOSURE  
STATEMENT UNDER 37 C.F.R. § 1.56**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

In accordance with the continuing duty of disclosure imposed by 37 C.F.R. § 1.56 to inform the Patent and Trademark Office of all references coming to the attention of each individual associated with the filing or prosecution of the subject application, which are or may be material to the patentability of any claim of the application, Attorneys for Applicants hereby direct the Examiner's attention to the references listed on the attached revised form PTO-1449 entitled "List of References Cited by Applicant." Legible copies of references BX to DJ are submitted herewith. Applicants respectfully request that the Examiner review the listed references and that the references be made of record in the file history of the application.

Since this Supplemental Information Disclosure Statement is being filed before the mailing of the first Office action on the merits, no fee is believed to be due according to 37 C.F.R. § 1.97(3). However, should the Patent and Trademark Office determine otherwise, please charge any required fee to Pennie & Edmonds LLP Deposit Account No. 16-1150. A copy of this sheet is enclosed for accounting purposes.


Respectfully submitted,

by: *Jaqueline Penn*  
Reg No. 43,492

Date: June 11, 2003

*Laura A. Coruzzi*  
\_\_\_\_\_  
Laura A. Coruzzi  
PENNIE & EDMONDS LLP  
1155 Avenue of the Americas  
New York, New York 10036-2711  
(212) 790-9090

30,742  
(Reg. No.)



Express Mail No. EV 335 012 US

# LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO.

7682-055-999

APPLICATION NO.

09/724,379

APPLICANT

Jin et al.

FILING DATE

November 28, 2000

GROUP

## U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	BX	5,993,824	11/99	Murphy et al.			
	BY	5,843,451	12/1/98	Compans et al.			
	BZ	6,060,308	5/9/00	Parrington			
	CA	6,168,943	1/2/01	Rose			

## FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION
	CB	WO 98/02530	1/22/98	PCT			
	CC	WO 96/10632	4/11/96	PCT			
	CD	WO 98/02179	1/22/98	PCT			
	CE	WO 91/03552	3/21/91	PCT			
	CF	WO 95/08634	3/30/95	PCT			
	CG	WO 00/18929	4/6/00	PCT			
	CH	WO 99/57284	11/11/99	PCT			
	CI	WO 93/06218	4/1/93	PCT			
	CJ	WO 00/53786	9/14/00	PCT			
	CK	EP 0 440 219	8/7/91	EP			

## OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)

	CL	Atreya, P. L. et al., 1998, J. Virol. 72:1452-1461
	CM	Buchholz, U. J. et al., 1999, J Virol 73(1): 251-259
	CN	Bukreyev et al. Recombinant respiratory syncytial virus from which the entire SH gene has been deleted grows efficiently in cell culture and exhibits site-specific attenuation in the respiratory tract of the mouse. J Virol. 1997 Dec;71(12):8973-82
	CO	Bukreyev et al. Recovery of infectious respiratory syncytial virus expressing an additional, foreign gene. J Virol. 1996 Oct;70(10):6634-41
	CP	Coates, H.V. et al., 1965, AM. J. Epid. 83:299-313
	CQ	Collins et al. Support plasmids and support proteins required for recovery of recombinant respiratory syncytial virus. Virology. 1999 Jul 5;259(2):251-5
	CR	Elango, N. et al., 1989, J Virol 63(3):1413-5
	CS	Firestone et al. Nucleotide sequence analysis of the respiratory syncytial virus subgroup A cold-passaged (cp) temperature sensitive (ts) cpts-248/404 live attenuated virus vaccine candidate. Virology. 1996 Nov 15;225(2):419-22
	CT	Frillingos et al. Cys-scanning mutagenesis: a novel approach to structure function relationships in polytopic membrane proteins. FASEB J. 1998 Oct;12(13):1281-99. Review
	CU	Garcia et al., 1993, Virology 195:243-247
	CV	Grosfeld, H. et al., 1995, J. Virol. 69:5677-5686
	CW	Hardy et al. The Cys(3)-His(1) motif of the respiratory syncytial virus M2-1 protein is essential for protein function. J Virol. 2000 Jul;74(13):5880-5
	CX	Hardy, R. W. et al., 1998, J. Virol. 72, 520-526
	CY	Hiebert, S. W. et al., 1985, J Virol 55(3):744-51
	CZ	Howorka et al. Improved protocol for high-throughput cysteine scanning mutagenesis. Biotechniques. 1998 Nov;25(5):764-6, 768, 770 passim
	DA	Jin et al. Recombinant human respiratory syncytial virus (RSV) from cDNA and construction of subgroup A and B chimeric RSV. Virology. 1998 Nov 10;251(1):206-14

RECEIVED

JUN 18 2003

TECH CENTER 1600/2900

✓	DB	Jin, H. et al., 1997, EMBO J. 16(6):1236-47
✓	DC	Karron, R. A. et al., 1997, J. Infect. Dis. 176:1428-1436
✓	DD	Lodish et al. Molecular Cell Biology, Third Ed. Scientific American Books, 1995
✓	DE	Murphy et al. An update on approaches to the development of respiratory syncytial virus (RSV) and parainfluenza virus type 3 (PIV3) vaccines. Virus Res. 1994 Apr;32(1):13-36. Review
✓	DF	Teng et al. Identification of the respiratory syncytial virus proteins required for formation and passage of helper-dependent infectious particles. J Virol. 1998 Jul;72(7):5707-16
✓	DG	Teng et al. Altered growth characteristics of recombinant respiratory syncytial viruses which do not produce NS2 protein. J Virol. 1999 Jan;73(1):466-73
✓	DH	Tolley et al. Identification of mutations contributing to the reduced virulence of a modified strain of respiratory syncytial virus. Vaccine. 1996 Dec;14(17-18):1637-46
✓	DI	Whitehead et al. Replacement of the F and G proteins of respiratory syncytial virus (RSV) subgroup A with those of subgroup B generates chimeric live attenuated RSV subgroup B vaccine candidates. J Virol. 1999 Dec;73(12):9773-80
✓	DJ	Worthington et al., 1996, Proc. Natl. Acad. Sci. 93:13754-13759
EXAMINER		DATE CONSIDERED
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.		